2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2778

Is There Any Gender Specific Difference in Discriminative Value of Inflammatory Back Pain Criteria?
Abstract Number: 1974

Is Ultrasound of the Hands Enough to Reveal Ongoing Subclinical Inflammation in Rheumatoid Arthritis Patients in Clinical Remission According to Composite Scores?
Abstract Number: 2683

Isolated Anti-La/SS-B Positivity in Patients Diagnosed with Primary Sjogren Syndrome: Analysis of 222 Patients from the Sjogren Big Data Cohort
Abstract Number: 435

It Takes Two, an Interdisciplinary Approach to Increasing Hydroxychloroquine Screening Adherence
Abstract Number: 1689

Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Abstract Number: 1688

Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Abstract Number: 1678

JAK STAT Kinase Cascade Regulates the IL-23/IL-17 Cytokine Axis in Psoriatic Arthritis
Abstract Number: 2489

Joint Damage Appears As Severe As Inflammation According to Physician Visual Analog Scales in Patients with Rheumatoid Arthritis Regardless of Disease Severity at 2 Sites, Which May Limit Results of a Treat-to-Target Strategy
Abstract Number: 2073

Jumonji Domain Containing Protein 3 (JMJD3) As a Novel Epigenetic Mechanism of Fibroblast Activation By Regulation of Fra-2
Abstract Number: 273

Juvenile Dermatomyositis Patient-Derived Induced Pluripotent Stem Cells Do Not Retain Disease Expression Signatures
Abstract Number: 1014

Juvenile Dermatomyositis: What Comes Next?
Abstract Number: 1435

KCa1.1 Potassium Channels Are a Novel Therapeutic Target on Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Abstract Number: 61

Killer Immunoglobulin-like Receptors Are Associated with Ankylosing Spondylitis
Abstract Number: 2122

KiSS1 Is a Regulator of ADAMTS4 and ADAMTS5 Expression and Is Post-Transcriptionally Regulated By Micro-RNA N105 in Human OA Chondrocytes
Abstract Number: 825

KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].